Key Benefits

• Drug of first choice for type 2 diabetes, particularly overweight
  patients when dietary management and exercise alone proves insufficient Guamet may be used as monotherapy or in combination with other oral anti-diabetic agents, or with insulin
  
  
• Unlike sulphonylureas, does not promote weight gain and produce hypoglycaemia
  
  
• Diminished burden of long-term diabetic complications in overweight type 2 diabetic patients treated with metformin as first-line therapy after failure to follow diet
  
  
• Reduces insulin resistance
  
  
• Guamet provides "very favourable" risk-benefits against the multiple burdens of type 2 diabetes
  
  
• Excellent candidate for the prevention of progression of impaired glucose tolerance to type 2 diabetes

Indications

• Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycemic control.